CA2901162C - Purification of rapamycin derivatives - Google Patents
Purification of rapamycin derivatives Download PDFInfo
- Publication number
- CA2901162C CA2901162C CA2901162A CA2901162A CA2901162C CA 2901162 C CA2901162 C CA 2901162C CA 2901162 A CA2901162 A CA 2901162A CA 2901162 A CA2901162 A CA 2901162A CA 2901162 C CA2901162 C CA 2901162C
- Authority
- CA
- Canada
- Prior art keywords
- purification
- rapamycin derivatives
- biolimus
- formula
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799857P | 2013-03-15 | 2013-03-15 | |
| US61/799,857 | 2013-03-15 | ||
| PCT/US2014/030602 WO2014145780A1 (en) | 2013-03-15 | 2014-03-17 | Purification of rapamycin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2901162A1 CA2901162A1 (en) | 2014-09-18 |
| CA2901162C true CA2901162C (en) | 2021-06-01 |
Family
ID=51538094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2901162A Active CA2901162C (en) | 2013-03-15 | 2014-03-17 | Purification of rapamycin derivatives |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9598439B2 (enExample) |
| EP (1) | EP2972258B1 (enExample) |
| JP (4) | JP2016519086A (enExample) |
| CN (2) | CN105102967B (enExample) |
| CA (1) | CA2901162C (enExample) |
| ES (1) | ES2897473T3 (enExample) |
| SG (3) | SG10202112135VA (enExample) |
| WO (1) | WO2014145780A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2777841C (en) | 2009-11-02 | 2017-01-17 | Francis M. Creighton | Magnetomotive stator system and methods for wireless control of magnetic rotors |
| CA2901162C (en) | 2013-03-15 | 2021-06-01 | Biosensors International Group, Ltd. | Purification of rapamycin derivatives |
| CN109851626B (zh) * | 2019-01-08 | 2021-11-02 | 扬子江药业集团四川海蓉药业有限公司 | 一种替西罗莫司的分离纯化方法 |
| CN116102576B (zh) * | 2021-11-09 | 2025-08-29 | 上海博畅医疗科技有限公司 | 一种优美莫司晶体的制造方法及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9713730D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| US20060198867A1 (en) * | 1997-09-25 | 2006-09-07 | Abbott Laboratories, Inc. | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
| US7452692B2 (en) | 2002-02-13 | 2008-11-18 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Method for extracting a macrolide from biomatter |
| TW200504079A (en) * | 2003-03-31 | 2005-02-01 | Biogal Gyogyszergyar | Crystallization and purification of macrolides |
| US7220755B2 (en) * | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| EP1697383B1 (en) * | 2003-12-05 | 2014-04-23 | Biocon Limited | Process for the purification of tacrolimus |
| JP4716280B2 (ja) * | 2004-03-01 | 2011-07-06 | テルモ株式会社 | Ｏ−アルキル化ラパマイシン誘導体の製造法 |
| CN1942476A (zh) * | 2004-04-14 | 2007-04-04 | 惠氏公司 | 纳巴霉素42－酯衍生物的区位特异合成 |
| EP1817314A1 (en) | 2004-12-01 | 2007-08-15 | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság | Non-hygroscopic and powdery amorphous pimecrolimus |
| KR20070107087A (ko) * | 2005-03-02 | 2007-11-06 | 와이어쓰 | 라파마이신의 정제 |
| US20060222627A1 (en) * | 2005-03-30 | 2006-10-05 | Andrew Carter | Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue |
| TW200736603A (en) * | 2005-12-07 | 2007-10-01 | Wyeth Corp | Methods for preparing crystalline rapamycin and measuring crystallinity of rapamycin compounds using differential scanning calorimetry |
| US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
| GB0601406D0 (en) * | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| EP1993610A2 (en) | 2006-03-07 | 2008-11-26 | Wyeth | Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
| US7812032B2 (en) * | 2006-07-25 | 2010-10-12 | Abbott Laboratories | Crystalline forms of rapamycin analogs |
| US7820812B2 (en) * | 2006-07-25 | 2010-10-26 | Abbott Laboratories | Methods of manufacturing crystalline forms of rapamycin analogs |
| JP2010509317A (ja) * | 2006-11-10 | 2010-03-25 | バイオコン リミテッド | 純粋な形態のラパマイシンならびにこの回収方法および精製方法 |
| JP5456321B2 (ja) | 2006-11-27 | 2014-03-26 | テルモ株式会社 | Ｏ−アルキル化ラパマイシン誘導体の製造方法およびｏ−アルキル化ラパマイシン誘導体 |
| US20080287675A1 (en) * | 2007-05-18 | 2008-11-20 | Abbott Laboratories | Cascade system |
| CN101077334A (zh) * | 2007-06-29 | 2007-11-28 | 济南康泉医药科技有限公司 | 含酪氨酸激酶抑制剂的抗癌组合物 |
| TW200948361A (en) * | 2008-05-26 | 2009-12-01 | Chunghwa Chemical Synthesis & Biotech Co Ltd | Method for synthesizing Biolimus A9 and the like and method for improving stability of the same |
| US20100055145A1 (en) * | 2008-08-29 | 2010-03-04 | Biosensors International Group | Stent coatings for reducing late stent thrombosis |
| US20100272773A1 (en) | 2009-04-24 | 2010-10-28 | Boston Scientific Scimed, Inc. | Use of Drug Polymorphs to Achieve Controlled Drug Delivery From a Coated Medical Device |
| CN102464669B (zh) * | 2010-11-17 | 2014-04-16 | 浙江海正药业股份有限公司 | 无定形依维莫司及其制备方法 |
| US8669360B2 (en) * | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
| WO2013028208A1 (en) * | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
| CN102786534A (zh) * | 2012-05-25 | 2012-11-21 | 上海现代制药股份有限公司 | 一种依维莫司的制备方法 |
| CA2901162C (en) | 2013-03-15 | 2021-06-01 | Biosensors International Group, Ltd. | Purification of rapamycin derivatives |
-
2014
- 2014-03-17 CA CA2901162A patent/CA2901162C/en active Active
- 2014-03-17 JP JP2016503426A patent/JP2016519086A/ja not_active Withdrawn
- 2014-03-17 SG SG10202112135VA patent/SG10202112135VA/en unknown
- 2014-03-17 WO PCT/US2014/030602 patent/WO2014145780A1/en not_active Ceased
- 2014-03-17 SG SG11201507406YA patent/SG11201507406YA/en unknown
- 2014-03-17 ES ES14763326T patent/ES2897473T3/es active Active
- 2014-03-17 CN CN201480013252.6A patent/CN105102967B/zh active Active
- 2014-03-17 SG SG10201707632PA patent/SG10201707632PA/en unknown
- 2014-03-17 CN CN201811056060.XA patent/CN108864149B/zh active Active
- 2014-03-17 EP EP14763326.7A patent/EP2972258B1/en active Active
-
2015
- 2015-09-14 US US14/853,711 patent/US9598439B2/en active Active
-
2017
- 2017-02-02 US US15/422,593 patent/US10202402B2/en active Active
-
2018
- 2018-12-18 US US16/224,140 patent/US10597406B2/en active Active
-
2019
- 2019-03-07 JP JP2019041615A patent/JP2019089848A/ja active Pending
-
2020
- 2020-03-02 US US16/806,770 patent/US11046711B2/en active Active
-
2021
- 2021-05-06 JP JP2021078418A patent/JP2021121601A/ja active Pending
- 2021-06-28 US US17/360,973 patent/US11780850B2/en active Active
-
2023
- 2023-08-25 JP JP2023136964A patent/JP2023164476A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105102967A (zh) | 2015-11-25 |
| JP2021121601A (ja) | 2021-08-26 |
| EP2972258A1 (en) | 2016-01-20 |
| JP2023164476A (ja) | 2023-11-10 |
| US10597406B2 (en) | 2020-03-24 |
| CA2901162A1 (en) | 2014-09-18 |
| WO2014145780A1 (en) | 2014-09-18 |
| US11780850B2 (en) | 2023-10-10 |
| CN108864149A (zh) | 2018-11-23 |
| US11046711B2 (en) | 2021-06-29 |
| US20170334928A1 (en) | 2017-11-23 |
| US10202402B2 (en) | 2019-02-12 |
| CN108864149B (zh) | 2022-04-05 |
| SG10201707632PA (en) | 2017-11-29 |
| EP2972258A4 (en) | 2016-12-21 |
| WO2014145780A4 (en) | 2014-11-20 |
| US20200270272A1 (en) | 2020-08-27 |
| US20220024947A1 (en) | 2022-01-27 |
| SG11201507406YA (en) | 2015-10-29 |
| SG10202112135VA (en) | 2021-12-30 |
| JP2019089848A (ja) | 2019-06-13 |
| EP2972258B1 (en) | 2021-08-04 |
| JP2016519086A (ja) | 2016-06-30 |
| US20190256527A1 (en) | 2019-08-22 |
| HK1218959A1 (zh) | 2017-03-17 |
| ES2897473T3 (es) | 2022-03-01 |
| US20160002262A1 (en) | 2016-01-07 |
| CN105102967B (zh) | 2018-10-12 |
| US9598439B2 (en) | 2017-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500263A1 (en) | New bicyclic derivatives | |
| PH12014501179B1 (en) | New bicyclic dihydroisoquinoline-1-one derivatives | |
| PH12015501934B1 (en) | New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
| MY199066A (en) | Processes for producing diazabicyclooctane compounds | |
| MY169043A (en) | New dihydroquinoline-2-one derivatives | |
| AU2012213775A8 (en) | 7-azaindole derivatives | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| MX2014014531A (es) | Derivados de aminoquinazolina y piridopirimidina. | |
| PH12015501363B1 (en) | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| MY169267A (en) | New aryl-quinoline derivatives | |
| MX2015017156A (es) | Inhibidores de bace. | |
| AU2014230812A8 (en) | Process for making benzoxazepin compounds | |
| MX353190B (es) | Derivados de isoquinolina y naftiridina. | |
| JO3063B1 (ar) | مركب مبتكر وطرق لانتاجه | |
| AU2012342891A8 (en) | 3-Cyanoaryl-1H-pyrrolo[2.3-b]pyridine derivatives | |
| MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k | |
| MX2015013224A (es) | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| CA2901162C (en) | Purification of rapamycin derivatives | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| MX2016006807A (es) | Derivados de imidazol. | |
| IN2013MU03704A (enExample) | ||
| MX2014012822A (es) | Proceso para elaborar derivados de naftiridina. | |
| TN2017000065A1 (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190306 |